Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation
Related Experiment Video
Updated: Feb 9, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Lorenzo Palleschi1, Eleonora Nunziata
1Hospital S. Giovanni-Addolorata, Unit of Geriatrics. ele.nunziata@gmail.com.
Insights
Older adults with atrial fibrillation (AF) face high stroke risk. Oral anticoagulation (OAC) effectively prevents clots, with newer non-vitamin K oral anticoagulants (NOACs) offering expanded treatment options for this population.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Atrial fibrillation (AF) significantly increases stroke risk, particularly in older adults.
- Oral anticoagulation (OAC) is the cornerstone of thromboembolic event prevention in AF patients.
- Traditional OAC agents include aspirin and vitamin-K antagonists (VKAs).
Purpose of the Study:
- To review practical considerations for selecting and using OAC in elderly patients with AF.
- To aid clinicians in making informed OAC treatment decisions for older adults.
- To discuss the role of novel oral anticoagulants in managing AF-related stroke risk.
Main Methods:
- Literature review of OAC agents for atrial fibrillation.
- Analysis of clinical guidelines and evidence for OAC use in the elderly.
- Discussion of practical aspects of OAC selection and administration.
Main Results:
- Older age is a major risk factor for stroke in AF.
- Non-vitamin K oral anticoagulants (NOACs) represent a significant advancement in OAC therapy.
- Effective OAC management is crucial for reducing thromboembolic disease in elderly AF patients.
Conclusions:
- OAC therapy is essential for stroke prevention in elderly patients with AF.
- NOACs provide valuable alternatives to VKAs, expanding therapeutic options.
- Careful consideration of patient-specific factors is necessary for optimal OAC selection in older adults.
Abstract:
Old age remains one of the strongest risk factors for stroke in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is the most effective way to prevent thromboembolic disease in patients with atrial fibrillation (AF). Until few years ago, aspirin and vitamin-K antagonists (VKAs) were the primary agents used to prevent thromboembolic disease in patients with AF. The approval of non-vitamin K oral anticoagulants (NOACs) has now expanded the range of therapeutic agents available to providers. The authors highlight practical considerations regarding the selection and use of OAC in older adults to aid clinical decision making.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Benefits of Self-Esteem
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Anticoagulant Drugs: Low-Molecular-Weight Heparins

